Implementation of the EU-law. Tom Van Paepegem Quality co-ordinator D.R.U.G.

Size: px
Start display at page:

Download "Implementation of the EU-law. Tom Van Paepegem Quality co-ordinator D.R.U.G."

Transcription

1 Implementation of the EU-law Tom Van Paepegem Quality co-ordinator D.R.U.G.

2 History (1) World War II: Experiments by Nazi-doctors 1946: Nüremberg process 1947: Nüremberg codeddd

3 History (2) 10 basic ethical principles of the Nüremberg Code: Voluntary consent of the human subject is absolutely essential. The experiment might not be at random or unneccessary in nature. The experiment must be based on the results of animal experimentation. The experiment should avoid all unnecessary physical and mental suffering and injury. Death or disabling injury might not be the expected outcome of the experiment. The degree of risk to be taken should never exceed the humanitarian importance of the problem to be solved by the experiment. Subjects must be protected against every possibility of injury, disability or death. The experiment should be conducted only by scientifically qualified persons. The subject is free to bring the experiment to an end through all stages of the experiment. The scientist must be prepared to terminate the experiment if continuation might result in injury, disability, or death of the subject.

4 History (3) 1962: Thalidomide incident (Softenon ) Drug was not registered Women did not known they were participating in a clinical trial 1964: Declaration of Helsinki World Medical Association (see previous speaker)

5 History (4) Different regulations by different countries: UK: ABPI report on good clinical research practice France: bonne practiques cliniques Germany: Grundsätze des BMJFFG für die Ordnumngsgemäβe Durchführund der Klinischen Prüfung Nordic Guidelines 1991: European guideline on GCP for non-registered drugs

6 History (5) 1993: WHO GCP guideline 1994: Austrian drug law including EU-GCP 1995: Swiss drug law including EU-GCP

7 History (6) 1996: ICH/GCP (International Conference on Harmonisation): Europe Japan North-America 2001: European guideline on GCP for all drugs

8 Important aspects EU-law (1) Applicable to all interventional clinical trials Clinical trials on minors: No incentives or financial inducements, except compensation Ethics Committee should have paediatric expertise or should have taken advice in the fields of paediatrics Clinical trials on incapacitated adults not able to give informed consent: No incentives or financial inducements, except compensation Ethics Committee should have expertise in the relevant disease or should have taken advice in the field of the relevant disease and patient population

9 Important aspects EU-law (2) Approval Ethics Committee (EC): Single opinion per country (explicit) Leading EC and local EC Taking into consideration: Relevance Risks Protocol and Investigator s Brochure Suitability investigator, facilities Recruitment of subjects and information for the subjects Indemnity Financial aspects Timelines: 60 calendar days (some exceptions: GMO, gene therapy, somatic cell therapy) Hierarchy in leading EC

10 Important aspects EU-law (3) Approval Competent Authority (implicit): Taking into consideration: Safety aspects related to the product Timelines: 60 calendar days (some exceptions: GMO, gene therapy, somatic cell therapy)

11 Important aspects EU-law (4) Following GCP required by law (EC, investigator, sponsor) CAVE: investigator-initiated clinical trials (= academic trials) The institution is the sponsor needs to fulfill all requirements of the sponsor as defined by GCP (insurance, monitoring, safety reporting, annual reporting, written quality management system, )

12 Important aspects EU-law (5) Safety reporting: Serious adverse event (SAE): Ethics Committees Investigators Expedited reporting (24-48h) Suspected unexpected serious adverse event (SUSAR): Ethics Committees Investigators Competent authorities Death or life-threatening: 7 calendar days Others: 15 calendar days

13 Belgian situation EU-law implemented (not only interventional trials, but also all experiments) Timelines Monocentric phase I clinical trials: 15 calendar days Other trials: 28 calendar days One clock-stop No-fault insurance for all experiments on human beings

Agenzia Italiana del Farmaco

Agenzia Italiana del Farmaco Agenzia Italiana del Farmaco The Italian Legislation and the work of the Italian Medicines Agency (AIFA) in the field of ethics of Clinical Trials Umberto Filibeck AIFA Head of GCP Inspectorate and GCP

More information

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004 Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive

More information

Belgian Center for Pharamcovigilance for medicines for Human use (BCPH): faggafmps.be

Belgian Center for Pharamcovigilance for medicines for Human use (BCPH): faggafmps.be Medicinal Products for Human Use - BELGIUM Competent authority Contact Details Contact Name 1 Federal Agency for Medicines and Health Products (FAMHP) / Agence Fédérale des Médicaments et des Produits

More information

OVERVIEW OF DIRECTIVE 2001/20. Paul Derbyshire. Background & History. Aims of Directive 2001/20

OVERVIEW OF DIRECTIVE 2001/20. Paul Derbyshire. Background & History. Aims of Directive 2001/20 OVERVIEW OF DIRECTIVE 2001/20 Paul Derbyshire Background & History CONDUCT OF TRIALS III/3976/88 (July 1991) ICH/135/95 (January 1997) 2001/20 75/318 Q,S,E Testing Part 4B: GCP 91/507 MEDICINAL PRODUCTS

More information

Regulatory and ethics bodies involved in approval process. CA - Submission for authorisation mandatory for

Regulatory and ethics bodies involved in approval process. CA - Submission for authorisation mandatory for Medicinal Products for Human Use - CZECH REPUBLIC Competent authority Contact Details Contact Name 1 State Institute for Control of Drugs- SÚKL (Státní ústav pro kontrolu léčiv) Phone +420 272 185 111

More information

APPLICATION FORM. Application for a Recognised Research Ethics Committee (REC) Opinion on a Clinical Trial on a Medicinal Product for Human Use.

APPLICATION FORM. Application for a Recognised Research Ethics Committee (REC) Opinion on a Clinical Trial on a Medicinal Product for Human Use. APPLICATION FORM Application for a Recognised Research Ethics Committee (REC) Opinion on a Clinical Trial on a Medicinal Product for Human Use. Form 1 This application form should be completed and submitted

More information

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949 ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are

More information

Good Clinical Practice

Good Clinical Practice Dublin Academic Medical Centre Good Clinical Practice Patrick Murray, MD, FASN, FRCPI Professor, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland patrick.murray@ucd.ie

More information

Research Ethics and Good Clinical Practice. Dr. Rosie Mayston, Centre for Global Mental Health, Institute of Psychiatry, King s College London

Research Ethics and Good Clinical Practice. Dr. Rosie Mayston, Centre for Global Mental Health, Institute of Psychiatry, King s College London Research Ethics and Good Clinical Practice Dr. Rosie Mayston, Centre for Global Mental Health, Institute of Psychiatry, King s College London History of Research Ethics Nuremberg Code End of WWII Nazi

More information

Composition of Ethics Committees

Composition of Ethics Committees Composition of Ethics Committees TEMIDAYO O OGUNDIRAN MBBS (IBADAN), MHSC (TORONTO), FACS, FRCS ( EDINBURGH), FWACS DIVISION OF ONCOLOGY, DEPARTMENT OF SURGERY, UNIVERSITY OF IBADAN AND UNIVERSITY COLLEGE

More information

RSC/CT Det. no. 1/2013

RSC/CT Det. no. 1/2013 RSC/CT Det. no. 1/2013 Protocol 1631-P The English version of this Determination was prepared in order to help comprehension by non-italian mother tongue users, but is NOT an official document. Please

More information

Impact of Clinical EU Directive on the implementation of Early development studies in Europe

Impact of Clinical EU Directive on the implementation of Early development studies in Europe Impact of Clinical EU Directive on the implementation of Early development studies in Europe Alain Patat, M.D. Translational Development Wyeth Research Paris, France AGAH-Club Phase 1 1 st Syposium Strasbourg

More information

State Institute for Control of Drugs-/ Státní ústav pro control léčiv (SÚKL) Regulatory and ethics bodies involved in approval process

State Institute for Control of Drugs-/ Státní ústav pro control léčiv (SÚKL) Regulatory and ethics bodies involved in approval process Medical Devices - CZECH REPUBLIC Competent authority Contact Details Contact Name 1 State Institute for Control of Drugs-/ Státní ústav pro control léčiv (SÚKL) Phone +420 272 185 111 Fax +420 271 732

More information

Melbourne Health Guidelines Cover Sheet

Melbourne Health Guidelines Cover Sheet Melbourne Guidelines Cover Sheet NAME OF DEPARTMENT OFFICE FOR RESEARCH NAME OF DOCUMENT Clinical Trials Involving Therapeutic Products and Other Clinical Research NUMBER 18.8 ASSOCIATED MELBOURNE HEALTH

More information

Annual Research Administrators Symposium IRB Compliance. Thursday, July 31, 2014

Annual Research Administrators Symposium IRB Compliance. Thursday, July 31, 2014 Annual Research Administrators Symposium IRB Compliance Thursday, July 31, 2014 Why IRB Compliance Is Required for Grant Submissions Topics to Cover Today What is an IRB? Why IRB review is required? Regulatory

More information

Functional Classification of Medicine

Functional Classification of Medicine Research on Humans Functional Classification of Medicine Medicine and medical intervention can take any of five forms: (1) Therapeutic (curative): seeks to cure a disease or ailment. (2) Palliative: seeks

More information

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010 IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized

More information

Regulatory and ethical requirements in medical devices studies. France

Regulatory and ethical requirements in medical devices studies. France Regulatory and ethical in medical devices studies France SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within

More information

Guidance for applicants for ethics committee opinion on the conduct of a clinical trial of pharmaceuticals

Guidance for applicants for ethics committee opinion on the conduct of a clinical trial of pharmaceuticals KLH-EC-01 APPLICATION FOR ETHICS COMMITTEE OPINION ON THE CONDUCT OF A CLINICAL TRIAL IN THE CZECH REPUBLIC requirements governing the documentation to be submitted This guideline is being published in

More information

Regulatory and ethical requirements in medical device studies. Finland

Regulatory and ethical requirements in medical device studies. Finland Regulatory and ethical in medical device studies Finland SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within

More information

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing

More information

Public Consultation Paper: Assessment of the Functioning of the Clinical Trials Directive 2001/20/EC

Public Consultation Paper: Assessment of the Functioning of the Clinical Trials Directive 2001/20/EC Public Consultation Paper: Assessment of the Functioning of the Clinical Trials Directive 2001/20/EC National Institute for Health Research (NIHR CRN) and UKCRC Registered Clinical Trials Units Response

More information

WRITTEN SUBMISSION ON THE OPERATION OF THE CLINICAL TRIALS DIRECTIVE (DIRECTIVE 2001/20/EC) AND PERSPECTIVES FOR THE FUTURE

WRITTEN SUBMISSION ON THE OPERATION OF THE CLINICAL TRIALS DIRECTIVE (DIRECTIVE 2001/20/EC) AND PERSPECTIVES FOR THE FUTURE WRITTEN SUBMISSION ON THE OPERATION OF THE CLINICAL TRIALS DIRECTIVE (DIRECTIVE 2001/20/EC) AND PERSPECTIVES FOR THE FUTURE ECRIN (European Clinical Research Infrastructures Network) EORTC (European Organization

More information

Clinical trials from CRA s point of view

Clinical trials from CRA s point of view Clinical trials from CRA s point of view Dr Jacek S Gregorczyk MPharmS, PhD Clinical Research Associate (CRA) at MDS Pharma Services UK office - a global CRO REGULATION of CLINICAL TRIALS World Medical

More information

Ethical Principles in Clinical Research

Ethical Principles in Clinical Research Ethical Principles in Clinical Research Christine Grady NIH Clinical Center Department of Bioethics No conflicts of interest. Views presented are mine and do not necessarily represent positions or policies

More information

Ethical Issues in Clinical Trial & Development of Regulation Policy on Clinical Research

Ethical Issues in Clinical Trial & Development of Regulation Policy on Clinical Research Ethical Issues in Clinical Trial & Development of Regulation Policy on Clinical Research Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Department

More information

Life cycle of a clinical trial. IMB Clinical Trial Seminar June 19 th Dr. Agnieszka Przybyszewska, MD, MSc, PhD, PGDipPharmMed.

Life cycle of a clinical trial. IMB Clinical Trial Seminar June 19 th Dr. Agnieszka Przybyszewska, MD, MSc, PhD, PGDipPharmMed. Life cycle of a clinical trial IMB Clinical Trial Seminar June 19 th Dr. Agnieszka Przybyszewska, MD, MSc, PhD, PGDipPharmMed. Life cycle of a clinical trial In each MS concerned EUDRA-CT S P O N S O R

More information

Comment by the Federal Institute for Drugs and Medical Devices in coordination with the Paul Ehrlich Institute and the Federal Ministry of Health

Comment by the Federal Institute for Drugs and Medical Devices in coordination with the Paul Ehrlich Institute and the Federal Ministry of Health Comment by the Federal Institute for Drugs and Medical Devices in coordination with the Paul Ehrlich Institute and the Federal Ministry of Health on the public consultation 1 ASSESSMENT OF THE FUNCTIONING

More information

Quality Assurance in Clinical Trials

Quality Assurance in Clinical Trials Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:

More information

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL Assemble Essential Documents in Trial Master File (TMF) Appendix 1 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.2 Before the Clinical Phase of the Trial Commences During this planning stage

More information

RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs. Greater Manchester Mental Health NHS Foundation Trust

RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs. Greater Manchester Mental Health NHS Foundation Trust RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs Greater Manchester Mental Health NHS Foundation Trust Title of Standard Operating Procedure: RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs

More information

Guide to Clinical Trial Applications

Guide to Clinical Trial Applications Guide to Clinical Trial Applications AUT-G0001-11 29 MAY 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS 3 1

More information

Clinical Research: A Multifaceted Discipline

Clinical Research: A Multifaceted Discipline Clinical Research: A Multifaceted Discipline Anuradha Kulkarni a, Arun Bhatt b* a Senior Associate - Medical & Regulatory Affairs, Clininvent Research Pvt Ltd, A-302, Everest Chambers, Marol Naka, Andheri

More information

Pharmacovigilance and safety reporting for sponsored ATIMPs/CTIMPs

Pharmacovigilance and safety reporting for sponsored ATIMPs/CTIMPs Joint Research Management Office (JRMO) Standard Operating Procedure (SOP) for: Pharmacovigilance and safety reporting for sponsored ATIMPs/CTIMPs SOP Number: 26a Version Number: 13.0 Effective Date: 31

More information

Regulatory and ethical requirements in medical device studies DENMARK

Regulatory and ethical requirements in medical device studies DENMARK Regulatory and ethical in medical device studies DENMARK SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within

More information

Safety Reporting Part 1: For Clinical Trials of Investigational Medicinal Products (CTIMPs)

Safety Reporting Part 1: For Clinical Trials of Investigational Medicinal Products (CTIMPs) Part 1: For Clinical Trials of Investigational Medicinal Products (CTIMPs) Version 1.4 Effective date: 1 December 2011 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision

More information

What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance

What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance Vol. 9, No. 2, February 2013 Happy Trials to You What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance Reprinted from the Guide to Good Clinical Practice with permission of Thompson Publishing

More information

Regulatory and ethics bodies involved in approval process. CA - Registration requirements for clinical trials

Regulatory and ethics bodies involved in approval process. CA - Registration requirements for clinical trials Nutrition - LUXEMBOURG Competent authority Contact Details Contact Name 1 Ministry of Health Phone +352 247-85592 / 96 Fax +352 24795615 Email General info@ ms.etat.lu Address Allée Marconi - Villa Louvigny

More information

Health Registration and Training Center (HRTC/ENKK) , Mail: 1380 P.O. Box 1188 (Street: Zrinyi u. 3.

Health Registration and Training Center (HRTC/ENKK) , Mail: 1380 P.O. Box 1188 (Street: Zrinyi u. 3. Medical Devices - HUNGARY Competent authority Contact Details Contact Name 1 Health Registration and Training Center (HRTC/ENKK) Contact Name 2 Department of Medical Devices Phone +36 1 235-7914, +36 1

More information

RESEARCH IN HUMAN SUBJECTS OTHER THAN CLINICAL TRIALS OF INVESTIGATIONAL MEDICINAL PRODUCTS

RESEARCH IN HUMAN SUBJECTS OTHER THAN CLINICAL TRIALS OF INVESTIGATIONAL MEDICINAL PRODUCTS Page 1 of 5 RESEARCH IN HUMAN SUBJECTS OTHER THAN CLINICAL TRIALS OF INVESTIGATIONAL MEDICINAL PRODUCTS After ethical review guidance for sponsors and investigators This document sets out important guidance

More information

EU Clinical Trial Regulation A view from the Industry

EU Clinical Trial Regulation A view from the Industry Conference EU Clinical Trial Regulation EU Clinical Trial Regulation A view from the Industry Judith Creba, Executive Director, EU Regulatory Strategy, Novartis Pharma AG University of Basel, Law Faculty

More information

Regulatory and ethics bodies involved in approval process for trials. National Ethics Committee; Agency for Data Protection;

Regulatory and ethics bodies involved in approval process for trials. National Ethics Committee; Agency for Data Protection; Nutrition/InterventionaI - LUXEMBOURG Competent authority Contact Details Contact Name 1 Ministry of Health Phone +352 247-85592 / 96 Fax +352 24795615 Email General info@ ms.etat.lu Address Allée Marconi

More information

Competent federal higher authority ("Bundesoberbehörde- BOB")

Competent federal higher authority (Bundesoberbehörde- BOB) Nutrition/InterventionaI - GERMANY Competent authority Contact Details Contact Name 1 Competent federal higher authority ("Bundesoberbehörde- BOB") Contact Name 2 Federal Institute for Drugs and Medical

More information

Regulatory and ethical requirements in medical devices studies. Turkey

Regulatory and ethical requirements in medical devices studies. Turkey Regulatory and ethical in medical devices studies Turkey SECTIONS A.Type of research H. Data Protection SECTIONS A.Type of research H. Data Protection We have differentiated 8 types of research: Medical

More information

Good Clinical Practice, GCP. Clinical Trials 101 GCIG CCRN QA

Good Clinical Practice, GCP. Clinical Trials 101 GCIG CCRN QA Good Clinical Practice, GCP Clinical Trials 101 GCIG CCRN QA Monica Bacon/Adriana Chavez-Blanco GCIG-CCRN Background: 1949 The Nuremburg Code 1964 Declaration of Helsinki (World Medical Association) 1990

More information

REVISION OF THE CLINICAL TRIALS DIRECTIVE 2001/20/EC UK RESPONSE TO CONCEPT PAPER

REVISION OF THE CLINICAL TRIALS DIRECTIVE 2001/20/EC UK RESPONSE TO CONCEPT PAPER REVISION OF THE CLINICAL TRIALS DIRECTIVE 2001/20/EC UK RESPONSE TO CONCEPT PAPER Introduction This letter provides the UK Government s response to the Commission s public consultation on the proposed

More information

Highlights of the proposed Clinical Trials Regulation in Europe

Highlights of the proposed Clinical Trials Regulation in Europe Highlights of the proposed Clinical Trials Regulation in Europe Dr Daryl Rees 22 January 2013 Proposed Clinical Trials Regulation On 17July 2012, the Commission adopted the proposal for a "Clinical Trials

More information

Regulatory and ethical requirements in medical devices studies. Portugal

Regulatory and ethical requirements in medical devices studies. Portugal Regulatory and ethical in medical devices studies Portugal SECTIONS A.Type of research H. Data Protection SECTIONS A.Type of research H. Data Protection We have differentiated 8 types of research: Medical

More information

Regulatory Newsletter January - March 2014

Regulatory Newsletter January - March 2014 Regulatory Newsletter January - March 2014 Introduction CROMSOURCE is committed to sharing our expertise with our clients and future clients. This reflects the first part of our Advise Agree Deliver motto!

More information

Risk-adapted approach to clinical trial regulation and monitoring

Risk-adapted approach to clinical trial regulation and monitoring European Leukemia Net Workshop Mannheim, February 1st, 2011 Risk-adapted approach to clinical trial regulation and monitoring Jacques Demotes jacques.demotes@inserm.fr www.ecrin.org Risk-based approach

More information

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor. POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional

More information

OFFICE FOR RESEACH PROCEDURE. Sponsor Responsibilities in Investigator Initiated Studies

OFFICE FOR RESEACH PROCEDURE. Sponsor Responsibilities in Investigator Initiated Studies OFFICE FOR RESEACH PROCEDURE Sponsor Responsibilities in Investigator Initiated Studies 1. Purpose: To define Sponsor Responsibilities in the conduct of Investigator driven studies. 2. Scope: All phases

More information

Comments of the University-based Network of Coordinating Centers for Clinical Trials

Comments of the University-based Network of Coordinating Centers for Clinical Trials , on the Public Consultation Paper of the European Commission on the Functioning of the Clinical Trials Directive, issued 09 th of October 2009 General Comments: The Network of Coordinating Centers for

More information

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) 5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) GCP Requirements and Compliance Dr. Katalina Mettke BfArM, Germany Agenda Specialities of Early Development Trials Examples

More information

Regulatory and ethical requirements in medical devices studies. Italy

Regulatory and ethical requirements in medical devices studies. Italy Regulatory and ethical in medical devices studies Italy SECTIONS A.Type of research H. Data Protection SECTIONS A.Type of research H. Data Protection We have differentiated 8 types of research: Medical

More information

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor. SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities

More information

N : AAHRPP-SOP-057 / REV 003 N ENGLISH VERSION :188

N : AAHRPP-SOP-057 / REV 003 N ENGLISH VERSION :188 SOP FOR THE SUBMISSION OF THE EXPERIMENT ANNUAL REPORT TO THE ETHICS COMMITTEE N : AAHRPP-SOP-057 / REV 003 N ENGLISH VERSION :188 "Please do take into account that this is a translation of the original

More information

Clinical Trials application process, legislation & guidelines

Clinical Trials application process, legislation & guidelines Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission

More information

Primary Care mcta 2013: Guidance for use

Primary Care mcta 2013: Guidance for use GUIDANCE ON USE OF THE MODEL CLINICAL TRIAL AGREEMENT FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY SPONSORED RESEARCH IN PRIMARY CARE (PRIMARY CARE mcta, 2013 VERSION) Background to the development

More information

VERSION: 21 st June Date of Publication: 15 th March C/ CAMPEZO, 1 EDIFICIO MADRID Tel.: Fax:

VERSION: 21 st June Date of Publication: 15 th March C/ CAMPEZO, 1 EDIFICIO MADRID Tel.: Fax: Memorandum on Collaboration and Exchange of Information between the Spanish Agency of Medicinal Products and Medical Devices and Ethics Committees for investigation with medicinal products VERSION: 21

More information

Pharmacovigilance in Asia: The China Perspectives. Disclaimer

Pharmacovigilance in Asia: The China Perspectives. Disclaimer Pharmacovigilance in Asia: The China Perspectives Rebecca Wang, MD, FRCP, FACC Head, Product Development Drug Safety Operation, Asia Pacific Roche Shanghai Disclaimer The views and opinions expressed in

More information

Implementing the Directive - from the Swedish Perspective. Kerstin Westermark MD, PhD, Assoc Prof Head of Division of Clinical Trials

Implementing the Directive - from the Swedish Perspective. Kerstin Westermark MD, PhD, Assoc Prof Head of Division of Clinical Trials Implementing the Directive - from the Swedish Perspective Kerstin Westermark MD, PhD, Assoc Prof Head of Division of Clinical Trials Previous system in Sweden CA (LVFS 1996:17) Approval of applications

More information

STANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File

STANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File Research Department STANDARD OPERATING PROCEDURE STH Researcher SOP History CSUH 00/016 SOP Number A116 Created STH Research Department (TL) Reviewed by STH Research Department (AL) 06 August 2009 Superseded

More information

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products. 1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, 09/02/2011 SANCO/C/8/PB/SF D(2011) 143488 REVISION OF THE CLINICAL TRIALS DIRECTIVE

More information

GCP/Clinical Investigation in Japan

GCP/Clinical Investigation in Japan GCP/Clinical Investigation in Japan 27-28 August, 2018 Shinwa Shibata Office of Non-clinical and Clinical Compliance Pharmaceuticals and Medical Devices Agency 1 Today s Agenda 1. Japanese-GCP (J-GCP)

More information

Track III: International Clinical Trials: Global Compliance Norms and EU Focus

Track III: International Clinical Trials: Global Compliance Norms and EU Focus Track III: International Clinical Trials: Global Compliance Norms and EU Focus EU Focus Emmanuelle Voisin, PhD Principal, Voisin Consulting May 2008 Rationale Clinical trials in EU important part of health

More information

GCP Basics - refresher

GCP Basics - refresher p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History

More information

Clinical Trials How, Why and When? Candidate to Market 16 th May 2012 Kirsty Kwiatkowski

Clinical Trials How, Why and When? Candidate to Market 16 th May 2012 Kirsty Kwiatkowski Clinical Trials How, Why and When? Candidate to Market 16 th May 2012 Kirsty Kwiatkowski Agenda Why are clinical trials conducted? History Guidelines and Regulations When are trials conducted? Requirements

More information

Code break is also known as breaking the blind and involves un-blinding a participant so that the treatment allocation is made known.

Code break is also known as breaking the blind and involves un-blinding a participant so that the treatment allocation is made known. 1. INTRODUCTION This SOP has been produced in accordance with Medicines for Human Use (Clinical Trials) Regulations 2004. This SOP will outline the procedure for breaking the study code in a NUH sponsored

More information

Patient Handbook on Stem Cell Therapies

Patient Handbook on Stem Cell Therapies Patient Handbook on Stem Cell Therapies WWW.ISSCR.ORG WWW.CLOSERLOOKATSTEMCELLS.ORG Patient Handbook on Stem Cell Therapies Introduction We have all heard about the extraordinary promise that stem cell

More information

ENTR/F/2/SF D(2009) Assessment of the Functioning of the Clinical Trials Directive 2001/20/EC Public Consultation

ENTR/F/2/SF D(2009) Assessment of the Functioning of the Clinical Trials Directive 2001/20/EC Public Consultation Geschäftsstelle.. D- To European Commission Enterprise and Industry Directorate-General Consumer Goods Pharmaceuticals Via Mail Entr-pharmaceuticals@ec.europa.eu Heidelberg, January 9, 2010 ENTR/F/2/SF

More information

ANNEX. CHAPTER I General principles

ANNEX. CHAPTER I General principles ANNEX REGULATIONS on the authorisation by the NMA of clinical trials/notification to the National Medicines Agency of non-interventional studies on medicinal products for human use in Romania CHAPTER I

More information

Human Research Protection Program Policy

Human Research Protection Program Policy Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may

More information

Marie-Claire Rickard (RG and GCP Manager) Rachel Fay (RG and GCP Manager) Elizabeth Clough (R&D Governance Operations Manager)

Marie-Claire Rickard (RG and GCP Manager) Rachel Fay (RG and GCP Manager) Elizabeth Clough (R&D Governance Operations Manager) Standard Operating Procedures (SOP) for: For researchers: Pharmacovigilance and Safety Reporting for Sponsored CTIMPs/ATMP SOP Number: 026a Version Number: 12.0 Effective Date: 21/4/16 Review Date: 21/4/18

More information

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

1201 Maryland Avenue SW, Suite 900, Washington, DC , 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org December 28, 2010 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,

More information

Clinical Trials Environment EU Legislation: Ausblick auf die neue Gesetzgebung für klinische Prüfungen

Clinical Trials Environment EU Legislation: Ausblick auf die neue Gesetzgebung für klinische Prüfungen The Future of the Regulatory Berlin, 31.05.2013 Clinical Trials Environment EU Legislation: Qualifizierungstag für Study Nurses Ausblick auf die neue Gesetzgebung für klinische Prüfungen Dr. med. Ingrid

More information

SAE Reporting Timelines, Causality Assessment And Compensation. Pawandeep Kaur Associate Medical Director CDSA

SAE Reporting Timelines, Causality Assessment And Compensation. Pawandeep Kaur Associate Medical Director CDSA SAE Reporting Timelines, Causality Assessment And Compensation Pawandeep Kaur Associate Medical Director CDSA Objective Background Important definitions SAE Reporting Timelines Causality Assessment Compensation

More information

Conducting Clinical Trials of Investigational Medicinal Products

Conducting Clinical Trials of Investigational Medicinal Products Title: Outcome Statement: Written By: Reviewed By: Conducting Clinical Trials of Investigational Medicinal Products Researchers in the Trust and research partners will be informed about the procedures

More information

European Academy of Hospital Pharmacy Biotechnology Educational Summit. Clinical trials David Gerrett (Acknowledgment Mark Howells)

European Academy of Hospital Pharmacy Biotechnology Educational Summit. Clinical trials David Gerrett (Acknowledgment Mark Howells) European Academy of Hospital Pharmacy Biotechnology Educational Summit Clinical trials David Gerrett (Acknowledgment Mark Howells) Objectives Have an appreciation and overview of clinical trials Understand

More information

Trial Approval in Early Drug Development: Current Experiences in The Netherlands (Phases 0, I, IIA)

Trial Approval in Early Drug Development: Current Experiences in The Netherlands (Phases 0, I, IIA) Trial Approval in Early Drug Development: Current Experiences in The Netherlands (Phases 0, I, IIA) Rokus de Zeeuw, Ph.D. Professor Emeritus of Toxicology and Bioanalysis Foundation for the Evaluation

More information

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products 1 Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products SECTION TITLE DOCUMENTS 1. Contact List Including details of relevant study site staff, responsible

More information

Joint Research Office of Doncaster & Bassetlaw

Joint Research Office of Doncaster & Bassetlaw Page 1 of 11 Hospitals NHS, Rotherham Doncaster & South Humber NHS and NHS Signatures: Role Name Function Date (DD-MM-YYYY) Signature Author Amy Beckitt Clinical Research Development Manager Reviewer Dr

More information

The Situation of Investigator Initiated Trials in Europe. Dr.N.Gökbuget

The Situation of Investigator Initiated Trials in Europe. Dr.N.Gökbuget The Situation of Investigator Initiated Trials in Europe Dr.N.Gökbuget Investigator Initiated Trials in Europe Difficulties and Possibilities 1. Situation for academic clinical trials after the EU directive

More information

A notice on the issuance of drug clinical trials, ethical review of the guiding principles

A notice on the issuance of drug clinical trials, ethical review of the guiding principles 药物临床试验伦理审查工作指导原侧.doc 的翻译 A notice on the issuance of drug clinical trials, ethical review of the guiding principles State Food and Drug Administration Note [2010] No. 436 November 2, 2010 Release A notice

More information

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical

More information

Clinical trial applications in the EU and US

Clinical trial applications in the EU and US Clinical trial applications in the EU and US Alain Patat, M.D. Translational Development Wyeth Research Paris, France AGAH-Club Phase 1 1 st Symposium Strasbourg 17-18 March 2005 Overview of the presentation

More information

Guide to Clinical Trial Applications

Guide to Clinical Trial Applications Guide to Clinical Trial Applications Deleted: 06 AUGUST 2014 AUT-G0001-9 DATE 29 JUNE 2015 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.

More information

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Nancy Detich, Ph.D., C.C.R.P. Senior Scientist, Clinical Strategy 18 November 2010 1 Objectives Identify the importance of accuracy,

More information

RESEARCH AUDIT Standard Operating Procedure

RESEARCH AUDIT Standard Operating Procedure Reference Number: UHB 236 Version Number: 2 Date of Next Review: 17 th Oct 2020 Previous Trust/LHB Reference Number: N/A RESEARCH AUDIT Standard Operating Procedure Introduction and Aim As a legal Sponsor

More information

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland Question 1: What laws or regulations apply to an application for conducting a clinical

More information

GUIDELINES FOR CONDUCTING CLINICAL TRIALS.

GUIDELINES FOR CONDUCTING CLINICAL TRIALS. GUIDELINES FOR CONDUCTING CLINICAL TRIALS. FOREWORD The purpose of Drug Registration is to ensure that a pharmaceutical product has been adequately tested and evaluated for safety, efficacy and quality,

More information

GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN MAKING AN ASSESSMENT OF CLINICAL INVESTIGATION NOTIFICATION

GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN MAKING AN ASSESSMENT OF CLINICAL INVESTIGATION NOTIFICATION EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.2 December 2008 GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN

More information

ETHICS COMMITTEE. TITLE: Safety Reporting STANDARD OPERATING PROCEDURE SOP006

ETHICS COMMITTEE. TITLE: Safety Reporting STANDARD OPERATING PROCEDURE SOP006 1 PURPOSE The purpose of this SOP is to describe the Peter MacCallum Cancer Centre (Peter Mac) Ethics Committee process for submission and handling of safety reports arising out of research reviewed by

More information

Ethics in Biomedical Research

Ethics in Biomedical Research EDUCATIONAL FORUM Ethics in Biomedical Research 1 Vina Vaswani, Vinodkumar C.S 1 2 2 Director, Centre of Ethics, Yenepoya University, Associate Professor, Department of Microbiology S.S Institute of Medical

More information

1 PROCEDURE S OBJECT 2 PROCEDURE S SCOPE 3 RESPONSIBILITIES AND AUTHORITIES

1 PROCEDURE S OBJECT 2 PROCEDURE S SCOPE 3 RESPONSIBILITIES AND AUTHORITIES SOP FOR THE DECLARATION OF NON COMPLIANCE, DEVIATION, VIOLATION, UNEXPECTED EVENTS OCCURRING DURING AN EXPERIMENT. N : AAHRPP-SOP-040 / REV005 N ENGLISH VERSION : 108 "Please do take into account that

More information

ICH GCP Revision and EU Clinical Trial Regulation

ICH GCP Revision and EU Clinical Trial Regulation ICH GCP Revision and EU Clinical Trial Regulation Sinead Curran, GCP/PhV Inspection Manager Irish Research Nurses Network Annual National Conference Friday, 17 November 2017 Overview Guideline for Good

More information

3. Human Biomedical Research. Defining Human Biomedical Research

3. Human Biomedical Research. Defining Human Biomedical Research PART B: SECTION III: HUMAN BIOMEDICAL RESEARCH HUMAN BIOMEDICAL RESEARCH 3. Human Biomedical Research Defining Human Biomedical Research 3.1. In this section, we consider what kinds of human biomedical

More information

Ethics and Clinical trials EU approach

Ethics and Clinical trials EU approach Ethics and Clinical trials EU approach The view I express are my own and do not necessarily reflect those of the European Commission. NO Yes EU Policy In his main speech after his re-election as President

More information

Central Committee for Research Involving Human Subjects/ Centrale Commissie Mensgebonden Onderzoek (CCMO) NB! if CCMO acts as CA:

Central Committee for Research Involving Human Subjects/ Centrale Commissie Mensgebonden Onderzoek (CCMO) NB!  if CCMO acts as CA: Medicinal Products for Human Use - NETHERLANDS Competent authority Contact Details Contact Name 1 Central Committee for Research Involving Human Subjects/ Centrale Commissie Mensgebonden Onderzoek (CCMO)

More information